Table 1.
Characteristics of patients | Stopped opioid treatment | Continued opioid treatment |
---|---|---|
No (%) of patients | 799 668 (57.4) | 594 434 (42.6) |
Mean (SD) age (years) | 59.8 (15.4; 5 missing) | 61.3 (12.6; 6 missing) |
No (%) of women | 70 299 (8.8) | 42 691 (7.2) |
No (%) currently married | 384 211 (48.0) | 300 073 (50.5) |
Residence location: | ||
No (%) in urban areas | 515 452 (64.5) | 344 722 (58.0) |
No (%) in rural areas | 284 216 (35.5) | 249 712 (42.0) |
Mean (SD) No of medical diagnoses | 2.9 (2.3) | 3.1 (2.2) |
No (%) of patients with 0 to ≥5 medical diagnoses: | ||
0 | 109 958 (13.8) | 51 935 (8.7) |
1 | 139 174 (17.4) | 97 395 (16.4) |
2 | 149 358 (18.7) | 116 378 (19.6) |
3 | 130 677 (16.3) | 106 613 (17.9) |
4 | 98 644 (12.3) | 81 674 (13.7) |
≥5 | 171 857 (21.5) | 140 439 (23.6) |
No (%) diagnosed with substance use disorders: | 116 830 (14.6) | 82 006 (13.8) |
Nicotine | 165 993 (20.8) | 145 973 (24.6) |
Alcohol | 85 205 (10.7) | 56 322 (9.5) |
Drug | 66 282 (8.3) | 46 102 (7.8) |
Cannabis | 25 467 (3.2) | 14 697 (2.5) |
Opioid | 16 213 (2.0) | 13 177 (2.2) |
Barbiturate | 3,276 (0.4) | 2,112 (0.4) |
No (%) of patients with mental health diagnoses: | 343 478 (42.9) | 289 636 (48.7) |
Affective disorders | 29 049 (3.6) | 22 898 (3.8) |
Schizophrenia | 15 637 (2.0) | 10 242 (1.7) |
Post-traumatic stress disorder | 144 758 (18.1) | 121 388 (20.4) |
Major depressive disorder) | 78 066 (9.8) | 70 570 (11.9) |
Other depressive disorders | 185 654 (23.2) | 159 747 (26.9) |
General anxiety disorder | 20 773 (2.6) | 18 631 (3.1) |
Anxiety otherwise unspecified | 81 315 (10.2) | 67 058 (11.3) |
Other psychiatric diagnoses | 12 912 (1.6) | 8,548 (1.4) |
Mean (SD) maximum daily morphine mg equivalents for opioid prescription | 26.8 (35.0; 2 missing) | 43.2 (66.1) |
Opioid treatment type: | ||
No (%) long acting opioids | 36 677 (4.6) | 97 970 (16.5) |
No (%) short acting opioids | 560 364 (70.1) | 386 743 (65.0) |
No (%) tramadol only | 202 627 (25.3) | 109 721 (18.5) |
SD=standard deviation.